title: Nanoparticle Albumin-bound Paclitaxel+Carboplatin Therapy for Small Cell Lung Cancer Combined with Squamous Cell Carcinoma and Interstitial Lung Disease.
abstract: It has recently been shown that nanoparticle albumin-bound paclitaxel (nab-PAC)+carboplatin (CBDCA) provides a favorable overall response rate in non-small cell lung cancer. This is the first case report of nab-PAC+CBDCA therapy in small cell lung cancer (SCLC). Our patient was a 72-year-old man with stage IV SCLC combined with squamous cell carcinoma and interstitial lung disease (ILD). We administered nab-PAC+CBDCA as a second-line chemotherapy. A partial response was evident after two cycles of chemotherapy, and no serious side effects occurred. The progression-free survival was 15 weeks. Second-line chemotherapy using nab-PAC+CBDCA was effective and well tolerated in an SCLC patient with ILD.
authors.affiliation: Department of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Japan.
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Azuma
authors.forename: Motohiro
authors.initials: M
authors.lastname: Tamiya
authors.forename: Takayuki
authors.initials: T
authors.lastname: Shiroyama
authors.forename: Akio
authors.initials: A
authors.lastname: Osa
authors.forename: Sawa
authors.initials: S
authors.lastname: Takeoka
authors.forename: Naoko
authors.initials: N
authors.lastname: Morishita
authors.forename: Hidekazu
authors.initials: H
authors.lastname: Suzuki
authors.forename: Norio
authors.initials: N
authors.lastname: Okamoto
authors.forename: Tomonori
authors.initials: T
authors.lastname: Hirashima
authors.forename: Ichiro
authors.initials: I
authors.lastname: Kawase
mesh_terms: D000368:Aged; D000418:Albumins / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D016190:Carboplatin / Q000008:administration & dosage*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D018572:Disease-Free Survival; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D008297:Male; D053758:Nanoparticles; D017239:Paclitaxel / Q000008:administration & dosage*; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: C520255:130-nm albumin-bound paclitaxel; D000418:Albumins; D016190:Carboplatin; D017239:Paclitaxel